Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Gastric disorder
Clinical narrative: COVID-19; Gastric disorder; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID-19) and GASTRIC DISORDER (Gastric disorder) in an adult female patient who received mRNA-1273 (Spikevax) for COVID-19 vaccination.    Co-suspect product included non-company product UPADACITINIB (RINVOQ) for Rheumatoid arthritis.    Concurrent medical conditions included Rheumatoid arthritis.   In 2022, the patient started UPADACITINIB (RINVOQ) (Oral) at an unspecified dose. On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19) and GASTRIC DISORDER (Gastric disorder). At the time of the report, COVID-19 (COVID-19) was resolving and GASTRIC DISORDER (Gastric disorder) outcome was unknown.        The action taken with mRNA-1273 (Spikevax) (Intramuscular) was unknown.       No concomitant medication were reported.  It was unknown if patient was enrolled in a COVID-19 vaccine trail.  The daily dose of moderna vaccine was reported as 1 in 1 once. It was reported that patient experienced non serious COVID-19 and stomach issues with RINVOQ(UPADACITINIB). The action taken and dechallenge were UNK and not applicable for the event COVID-19 and drug discontinued and UNK for the event gastric disorder with respect to drug RINVOQ. It was reported that the reporter's causality for the events COVID-19 and gastric disorder with RINVOQ(UPADACITINIB) was no reasonable possibility.  No treatment medication were reported.  Company comment: This is a spontaneous case concerning an adult female patient with no relevant medical history, who experienced the unexpected non-serious adverse events of special interest, COVID-19 (COVID-19) which occurred on unspecified day after receiving a dose of mRNA-1273 vaccine (dose number not specified). It was reported that patient experienced non serious COVID-19 and stomach issues with co-suspect RINVOQ(UPADACITINIB) non-company product for Rheumatoid arthritis which is concomitant medication. Patient was not hospitalized and no treatment details was  provided. Ongoing Covid 19 pandemia and co-suspect RINVOQ could be considered as confounder to the event. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.; Sender's Comments: This is a spontaneous case concerning an adult female patient with no relevant medical history, who experienced the unexpected non-serious adverse events of special interest, COVID-19 (COVID-19) which occurred on unspecified day after receiving a dose of mRNA-1273 vaccine (dose number not specified). It was reported that patient experienced non serious COVID-19 and stomach issues with co-suspect RINVOQ(UPADACITINIB) non-company product for Rheumatoid arthritis which is concomitant medication. Patient was not hospitalized and no treatment details was  provided. Ongoing Covid 19 pandemia and co-suspect RINVOQ could be considered as confounder to the event. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.